MIS-C: A COVID-19-as sociated condition between hypoimmunity and hyperimmunity.

Area of Science:

• Immunology
• Genetics
• Pediatrics

Background:

• Multisystem inflammatory syndrome in children (MIS-C) is a severe, rare complication of COVID-19.
• Understanding MIS-C's immunological, cellular, and genetic underpinnings is crucial for diagnostics and targeted therapies.

Purpose of the Study:

• To investigate the immunological, cellular, and genetic profiles of children with MIS-C.
• To identify potential biomarkers and therapeutic targets for MIS-C.

Main Methods:

• Serum cytokine analysis (IFN-α, IFN-β, IFN-γ, IL-6, IL-10, IL-17A, IL-12p70, TNF).
• Lymphocyte population analysis via flow cytometry.
• Next-generation sequencing (NGS) of 386 genes associated with autoimmune diseases, autoinflammation, and primary immunodeficiencies.

Main Results:

• MIS-C patients exhibited elevated serum IFN-γ and ILs, with significant heterogeneity.
• Flow cytometry revealed reduced T cell populations and increased B cells.
• Genetic analysis identified variants in 34 genes, with 83.3% of patients having at least one variant, notably in genes linked to autoimmune and autoinflammatory conditions.

Conclusions:

• Heterogeneous cytokine profiles suggest distinct MIS-C pathogenic pathways, with potential for cytokine-guided therapy.
• Genetic predispositions, combined with potential self-antigen exposure post-COVID-19, may drive immune dysregulation in MIS-C.
• Immunocytometric profiling could aid in timely identification of patients requiring targeted management for severe MIS-C.